# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Anupam Rama downgrades Replimune Group (NASDAQ:REPL) from Neutral to Underweight.
Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immun...
HC Wainwright & Co. analyst Robert Burns reiterates Replimune Group (NASDAQ:REPL) from Neutral to Neutral.